University of Minnesota to Overhaul Research Protections
By Jennifer Couzin-Frankel,
Science
| 06. 15. 2015
More than a decade after a young man committed suicide during a psychiatric clinical trial at the University of Minnesota—and a bioethicist there spent years lobbying for changes to the school’s clinical trials system—the university is announcing major changes to how it oversees trials and protects its most vulnerable research subjects. Last week, the school released a 75-page document describing an effort to restructure its system and calm its critics. Changes include tighter conflict-of-interest rules; a larger institutional review board (IRB) whose members will be compensated; improved training for researchers working with vulnerable populations, such as the severely mentally ill; and a board of external advisers to monitor the university’s efforts.
The report comes after two damning reviews earlier this year: one by a group of experts appointed by the Association for the Accreditation of Human Research Protection Programs and the other by the state’s Office of the Legislative Auditor. The first report examined protections for university clinical trial participants. Among other things, it found that many IRB members did not regularly attend meetings during the first half of 2014—the...
Related Articles
By Rhys Blakely, The Times | 06.24.2025
Scientists have created fertile mice from male genetic material alone, a breakthrough that could one day open the door to human babies who inherit their genes from two fathers.
The experiment, led by Professor Yanchang Wei at Shanghai Jiao Tong...
By Ron Leuty, San Francisco Business Times | 06.16.2025
23andMe's two-step sale to a nonprofit led by former CEO Anne Wojcicki is nothing more than a dance around California's genetic privacy law, state Attorney General Rob Bonta said in a filing late Monday, one day before a judge will...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Gina Kolata, The New York Times | 06.20.2025
A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need...